The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation

Journal of Nutritional Biochemistry

Volumn 24, Issue 2, 2013, Pages 496-504

  Androutsopoulos, Vasilis P ^a   Spandidos, Demetrios A ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Antiproliferation; Cytochrome P450 CYP1 enzymes; Diosmetin; Flavonoids; Liver cancer; Luteolin

Indexed keywords

CYTOCHROME P450 1A; CYTOSTATIC AGENT; DIOSMETIN; JANUS KINASE; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG METABOLISM; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; UPREGULATION; WESTERN BLOTTING;

CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSTATIC AGENTS; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLAVONOIDS; G2 PHASE CELL CYCLE CHECKPOINTS; HEP G2 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; LUTEOLIN; MAP KINASE KINASE 4; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84872805497     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2012.01.012     Document Type: Article

References (46)

1. Poon R.T., Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 2011, 7:937-945.
2. Kim N.Y., Sun J.M., Kim Y.J., Lee K.W., Kim J.H., Bang S.M., et al. Cisplatin-based combination chemotherapy for advanced hepatocellular carcinoma: a single centre experience before the sorafenib era. Cancer Res Treat 2010, 42:203-209.
3. Yue O.X., Liu X., Guo D.A. Microtubule-binding natural products for cancer therapy. Planta Med 2010, 76:1037-1043.
4. Wang L.M., Ren D.M. Flavopiridol, the first cyclin-dependent kinase inhibitor: recent advances in combination chemotherapy. Mini Rev Med Chem 2010, 10:1058-1070.
5. Mueller M., Lukas B., Novak J., Simoncini T., Genazzani A.R., Jungbauer A. Oregano: a source for peroxisome proliferator-activated receptor gamma antagonists. J Agric Food Chem 2008, 56:11621-11630.
6. Koukoulitsa C., Karioti A., Bergonzi M.C., Pescitelli G., Di Bari L., Skalitsa H. Polar constituents from the aerial parts of Origanum vulgare L. Ssp. Hirtum growing wild in Greece. J Agric Food Chem 2006, 54:5388-5392.
7. Doodstdar H., Burke M.D., Mayer R.T. Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 2000, 144:31-38.
8. Xie Y.Y., Yuan D., Yang J.Y., Wang L.H., Wu C.F. Cytotoxic activity of flavonoids from the flowers of Chrysanthemum morifolium on human colon cancer Colon205 cells. J Asian Nat Prod Res 2009, 11:771-778.
9. Bitis L., Kultur S., Melikoglu G., Ozsoy N., Can A. Flavonoids and antioxidant activity of Rosa agrestis leaves. Nat Prod Res 2010, 24:580-589.
10. AlGamdi N., Mullen W., Crozier A. Tea prepared from Anstatica hirerochuntica seeds contains a diversity of antioxidant flavonoids, chlorogenic acids and phenolic compounds. Phytochemistry 2011, 72:248-254.
11. Obmann A., Werner I., Presser A., Zehl M., Swoboda Z., Purevsuren S. Flavonoid C- and O-glycosides from the Mongolian medicinal plant Dianthus versicolor Fisch. Carbohydr Res 2011, in press.
12. Pandino G., Courts F.L., Lombardo S., Mauromicale G., Williamson G. Caffeoylquinic acids and flavonoids in the immature inflorescence of globe artichoke, wild cardoon and cultivated cardoon. J Agric Food Chem 2010, 58:1026-1031.
13. Kato A., Minoshima Y., Yamamoto J., Adachi I., Watson A.A., Nash R.J. Protective effects of dietary chamomile tea on diabetic complications. J Agric Food Chem 2008, 56:8206-8211.
14. Garcia-Gonzalez D.L., Romero N., Aparicio R. Comparative study of virgin olive oil quality from single varieties cultivated in Chile and Spain. J Agric Food Chem 2010, 58:12899-12905.
15. Seelinger G., Merfort I., Wolfle U., Schempp C.M. Anti-carcinogenic effects of the flavonoid luteolin. Molecules 2008, 13:2628-2651.
16. Androutsopoulos V., Arroo R.R., Wilsher N., Potter G.A. Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett 2009, 274:54-60.
17. Patterson L.H., Murray G.I. Tumor cytochrome P450 and drug activation. Curr Pharm Des 2002, 8:1335-1347.
18. Gribben J.G., Ryan D.P., Boyajian R., Urban R.G., Hedley M.L., Beach K., et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005, 11:4430-4436.
19. Loaiza-Pérez A.I., Kenney S., Boswell J., Hollingshead M., Alley M.C., Hose C., et al. Aryl hydrocarbon receptor activation of an antitumour aminoflavone: basis of selective toxicity for MCF-7 breast tumour cells. Mol Cancer Ther 2004, 3:715-725.
20. Androutsopoulos V.P., Papakyriakou A., Vourloumis D., Tsatsakis A.M., Spandidos D.A. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol Ther 2010, 126:9-20.
21. Androutsopoulos V., Arroo R.R., Hall J.F., Surichan S., Potter G.A. Antiproliferative and cytostatic effects of the natural product eupatorin on MDA-MB-468 human breast cancer cells due to CYP1 mediated metabolism. Breast Cancer Res 2008, 10:R39.
22. Ek M., Soderdahl T., Kuppers-Munther B., Edsbagge J., Anderson T.B., Bjorquist P., et al. Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem Pharmacol 2007, 74:496-503.
23. Uno S., Endo K., Ishida Y., Tateno C., Makishima M., Yoshizato K., et al. CYP1A1 and CYP1A2 expression: comparing humanized mouse lines and wild-type mice; comparing human and mouse hepatoma cell lines. Toxicol Appl Pharmacol 2009, 237:119-126.
24. Burke M.D., Mayer R.T. Ethoxyresorufin: direct fluorimetric assay of a microsomal O-dealkylation which is preferentially inducible by 3-methylcholanthrene. Drug Metab Dispos 1974, 2:583-588.
25. Hewitt N.J., Hewitt P. Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica 2004, 34:243-256.
26. Boehme K., Dietz Y., Hewitt P., Mueller S.O. Activation of p53 in HepG2 cells as surrogate to detect mutagens and promutagens in vitro. Toxicol Lett 2010, 198:272-281.
27. Priyadarsini R.V., Murugan R.S., Maitreyi S., Ramalingam K., Karunagaran D., Nagini S. The flavonoid quercetin induces cell cycle arrest and mitochondria-mediated apoptosis in human cervical cancer (HeLa) cells through p53 induction and NF-kB inhibition. Eur J Pharmacol 2010, 649:84-91.
28. Beedanagari S.R., Taylor R.T., Bui P., Wang F., Nickerson D.W., Hankinson O. Role of epigenetic mechanisms in differential regulation of the dioxin-inducible human CYP1A1 and CYP1B1 genes. Mol Pharmacol 2010, 78:608-616.
29. Netsch M.I., Gutmann H., Schmidlin C.B., Aydogan C., Drewe J. Induction of CYP1A by green tea extract in human intestinal cell lines. Planta Med 2006, 72:514-520.
30. Vrba J., Vrublova E., Modriansky M., Ulrichova J. Protropine and allocryptopine increase mRNA levels of cytochromes P450 1A in human hepatocytes and HepG2 cells independently of AhR. Toxicol Lett 2011, 203:135-141.
31. Androutsopoulos V.P., Tsatsakis A.M., Spandidos D.A. Cytochrome P450 CYP1A1: wider roles in cancer progression and prevention. BMC Cancer 2009, 9:187.
32. Androutsopoulos V.P., Papakyriakou A., Vourloumis D., Spandidos D.A. Comparative CYP1A1 and CYP1B1 substrate and inhibitor profile of dietary flavonoids. Bioorg Med Chem 2011, 19:2842-2849.
33. Cheng Z., Surichan S., Ruparelia K., Arroo R.R., Boarder M.R. Tangeretin and its metabolite 4D́-hydroxytetramethoxyflavone attenuate EGF-stimulated cell cycle progression in hepatocytes; role of inhibition at the level of mTOR/p70S6K. Brit J Pharmacol 2011, 162:1781-1791.
34. Atherton K.M., Mutch E., Ford D. Metabolism of the soyabean isoflavone daidzein by CYP1A2 and the extra-hepatic CYPs 1A1 and 1B1 affects biological activity. Biochem Pharmacol 2006, 72:624-631.
35. Androutsopoulos V.P., Ruparelia K., Arroo R.R., Tsatsakis A.M., Spandidos D.A. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology 2009, 264:162-170.
36. Zhang S., Yang X., Morris M.E. Combined effects of multiple flavonoids on breast cancer resistance protein (ABCG2)-mediated transport. Pharm Res 2004, 21:1263-1273.
37. Galvez M., Martin-Cordero C., Lopez-Lazaro M., Cortes F., Ayuso M.J. Cytotoxic effect of Plantago spp. on cancer cell lines. J Ethnopharmacol 2003, 88:125-130.
38. Wang P., Li S., Ownby S., Zhang Z., Yuan W., Zhang W. Ecdysteroids and a sucrose phenylpropanoid ester from Froelichia floridana. Phytochemistry 2009, 70:430-436.
39. Yeh P.Y., Chuang S.E., Yeh K.H., Song Y.C., Chang L.L.Y., Cheng A.L. Phosphorylation of p53 on Thr55 by ERK2 is necessary for doxorubicin-induced p53 activation and cell death. Oncogene 2004, 23:3580-3588.
40. Singh S., Upadhyay A.K., Ajay A.K., Bhat M.K. p53 regulates ERK activation in carboplatin induced apoptosis in cervical carcinoma: a novel target of p53 in apoptosis. FEBS Lett 2007, 581:289-295.
41. Topisirovic I., Gutierrez G.J., Chen M., Appella E., Borden K.L., Ronai Z.A. Control of p53 multimerisation by Ubc13 is JNK-regulated. Proc Natl Acad Sci USA 2009, 106:12676-12681.
42. Buschmann T., Potapova O., Bar-Shira A., Ivanov V.N., Fuchs S.Y., Henderson S., et al. Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol Cell Biol 2001, 21:2743-2754.
43. WAF1/CIP1 activation involved in the arsenic trioxide-induced human epidermoid carcinoma A431 cellular cytotoxicity. J Biomed Sci 2006, 13:113-125.
44. Zhang Q., Zhao X.H., Wang Z.I. Cytotoxicity of flavones and flavonols to a human esophageal squamus cell carcinoma cell line (KYSE-510) by induction of G2/M arrest and apoptosis. Toxicol In Vitro 2009, 23:797-807.
45. Walle T. Methylation of dietary flavonoids greatly improves their hepatic metabolic stability and intestinal absorption. Mol Pharmaceutics 2007, 6:826-832.
46. Heinz S.A., Henson D.A., Nieman D.C., Austin M.D., Jin F. A 12-week supplementation with quercetin does not affect natural killer cell activity, granulocyte oxidative burst activity or granulocyte phagocytosis in female human subjects. Br J Nutr 2010, 104:849-857.